This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Concept
|
alpha-Fetoproteins
|
|
Concept
|
Receptor, IGF Type 1
|
|
Concept
|
Integrin alpha5beta1
|
|
Concept
|
Hepatocyte Nuclear Factor 1-alpha
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
|
Concept
|
Integrin alpha5
|
|
Concept
|
Receptor, Platelet-Derived Growth Factor alpha
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Receptors, Urokinase Plasminogen Activator
|
|
Concept
|
Receptor, Platelet-Derived Growth Factor beta
|
|
Concept
|
Integrin alphaVbeta3
|
|
Academic Article
|
Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)
|
|
Academic Article
|
An alpha-fetoprotein-producing hepatoid adenocarcinoma of the endometrium.
|
|
Academic Article
|
PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
|
|
Academic Article
|
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
|
|
Academic Article
|
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.
|
|
Academic Article
|
Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
|
|
Academic Article
|
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.
|
|
Academic Article
|
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
|
|
Academic Article
|
Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.
|
|
Academic Article
|
The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.
|
|
Academic Article
|
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
|
- Receptor
- Platelet Derived Growth Factor
- alpha